Literature DB >> 10660086

Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells.

K Ohtani1, H Sakamoto, T Rutherford, Z Chen, K Satoh, F Naftolin.   

Abstract

In order to study ezrin function in tumor growth and invasion, we used two cell lines of human endometrial cancers. Ishikawa, the low-metastatic endometrial cancer cell line, and its subclone (mEIIL) with high-metastatic activity and higher ezrin expression were treated with a ezrin antisense phosphorothioate oligonucleotides (ePONs) pulse four times before the in vitro growth assay and Matrigel invasion assay. ePONs significantly suppressed the number of both cells that penetrated through Matrigel membrane (inhibition rate; 40.1 +/- 7.5% (Ishikawa), 42.7 +/- 2.4% (mEIIL), mean +/- SD, n = 6, P < 0.05, Student's t-test), whereas they showed no effect on cell proliferation. Ezrin expression at the protein level was inhibited by ePONs. These data suggest that ezrin expression is required for invasion. The association of high ezrin expression in mEIIL and its higher ability to migrate through Matrigel may at least in part indicate functional significance of ezrin in endometrial cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10660086     DOI: 10.1016/s0304-3835(99)00272-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

1.  Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes.

Authors:  C Tran Quang; A Gautreau; M Arpin; R Treisman
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

2.  Expression of ezrin in human embryonic, fetal, and normal adult tissues.

Authors:  Jian-Jun Xie; Fa-Ren Zhang; Li-Hua Tao; Zhuo Lü; Xiu-E Xu; Li-Yan Xu; En-Min Li
Journal:  J Histochem Cytochem       Date:  2011-08-10       Impact factor: 2.479

3.  Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Authors:  Aykan A Karabudak; Julie Hafner; Vivekananda Shetty; Songming Chen; Angeles Alvarez Secord; Michael A Morse; Ramila Philip
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-03       Impact factor: 4.553

4.  Screening differentially expressed genes in mouse hepatocarcinoma ascites cell line with high potential of lymphatic metastasis.

Authors:  Xiao-Nan Cui; Jian-Wu Tang; Li Hou; Bo Song; Li Li; Ji-Wei Liu
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

5.  FoxM1 influences mouse hepatocellular carcinoma metastasis in vitro.

Authors:  Ningning Zhang; Yunpeng Xie; Benke Li; Zhen Ning; Aman Wang; Xiaonan Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

6.  Increase in ezrin expression from benign to malignant breast tumours.

Authors:  Daphne Gschwantler-Kaulich; Camilla Natter; Stefan Steurer; Ingrid Walter; Almut Thomas; Mohamed Salama; Christian F Singer
Journal:  Cell Oncol (Dordr)       Date:  2013-10-16       Impact factor: 6.730

7.  Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro.

Authors:  Qing-Yong Chen; Wei Xu; De-Min Jiao; Li-Jun Wu; Jia Song; Jie Yan; Jian-Guo Shi
Journal:  Mol Cell Biochem       Date:  2013-02-22       Impact factor: 3.396

8.  Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.

Authors:  K D Geiger; P Stoldt; W Schlote; A Derouiche
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

9.  The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness.

Authors:  Yan Zhang; Mei-Yu Hu; Wei-Zhong Wu; Zhi-Jun Wang; Kang Zhou; Xi-Liang Zha; Kang-Da Liu
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-20       Impact factor: 4.553

10.  The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells.

Authors:  Hirokatsu Osawa; Christian A Smith; Young Shin Ra; Paul Kongkham; James T Rutka
Journal:  Neuro Oncol       Date:  2008-12-16       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.